Is Ozempic the Same as Mounjaro? The Active Ingredient, Receptor, and Clinical Difference That Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic and Mounjaro are not the same. Ozempic contains semaglutide, a single-receptor GLP-1 agonist. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist.
• Mounjaro produces greater average weight loss in head-to-head trials (15.3% vs 10.5% at 40 weeks) because the GIP receptor activation amplifies insulin response and fat metabolism.
• Nausea rates are similar (20-25% in both), but Mounjaro has higher injection-site reaction rates (4.2% vs 1.8%) due to larger injection volume.
• Both are FDA-approved for type 2 diabetes. Only Mounjaro's higher-dose version (marketed as Zepbound) and semaglutide's higher-dose version (marketed as Wegovy) are approved for weight loss in non-diabetic patients.

Direct answer (40-60 words)

No. Ozempic and Mounjaro are different medications with different active ingredients. Ozempic contains semaglutide, which activates only the GLP-1 receptor. Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors. The dual-receptor mechanism produces greater weight loss but similar nausea rates. Neither is interchangeable with the other.

Table of contents

1. The one-sentence answer most articles get wrong
2. The molecular difference: semaglutide vs tirzepatide
3. What the GIP receptor does (and why it matters for weight loss)
4. Head-to-head trial data: Mounjaro vs Ozempic
5. Side effect comparison: where the profiles diverge
6. Dosing schedules and titration differences
7. FDA approval status: diabetes vs obesity indications
8. The compounded question: are compounded versions the same?
9. Cost comparison and insurance coverage patterns
10. When Ozempic is the better choice
11. When Mounjaro is the better choice
12. The decision framework: which medication fits your situation
13. FAQ
14. Sources

The one-sentence answer most articles get wrong

Most comparison articles say "Ozempic and Mounjaro are both GLP-1 medications for diabetes and weight loss." That's technically wrong in a way that matters clinically.

Ozempic is a GLP-1 receptor agonist. Mounjaro is a GLP-1 and GIP receptor agonist. The GIP receptor is not a minor detail. It's the reason Mounjaro produces 40% more weight loss than Ozempic in direct comparison trials (Frias et al., New England Journal of Medicine, 2021). Calling Mounjaro "a GLP-1 medication" is like calling a hybrid car "a gasoline car." Technically true for one component, but it misses the mechanism that differentiates performance.

The second error: neither Ozempic nor Mounjaro is FDA-approved for weight loss. Ozempic is approved only for type 2 diabetes. The weight-loss-approved version of semaglutide is Wegovy (same active ingredient, higher dose). The weight-loss-approved version of tirzepatide is Zepbound (same active ingredient as Mounjaro, same dose range). The brand-name distinction matters for insurance coverage and prescribing patterns, even though the active ingredients are identical within each pair.

The molecular difference: semaglutide vs tirzepatide

Semaglutide (Ozempic, Wegovy) is a modified GLP-1 analog. The molecule has three changes from native human GLP-1:

1. An amino acid substitution at position 8 (alanine to aminoisobutyric acid) that prevents enzyme breakdown
2. A lysine substitution at position 26
3. A C18 fatty acid side chain attached via a linker, which binds to albumin in the blood and extends half-life to 7 days

The result is a once-weekly injection that activates only the GLP-1 receptor.

Tirzepatide (Mounjaro, Zepbound) is a dual agonist engineered to activate both GLP-1 and GIP receptors. The molecule is based on the GIP structure with modifications that allow cross-activation of GLP-1 receptors. It also has a C20 fatty acid side chain for albumin binding and a 5-day half-life, which supports once-weekly dosing.

The structural difference is intentional. Eli Lilly designed tirzepatide specifically to capture the benefits of both incretin hormones rather than GLP-1 alone.

What the GIP receptor does (and why it matters for weight loss)

GIP stands for glucose-dependent insulinotropic polypeptide. It's one of two incretin hormones released by the gut in response to food (the other is GLP-1). Both stimulate insulin secretion, but GIP does three additional things that GLP-1 does not:

1. Enhances fat storage in adipose tissue during feeding. This sounds counterproductive for weight loss, but chronic GIP receptor activation in the context of calorie deficit appears to shift fat metabolism toward oxidation rather than storage (Samms et al., Science Translational Medicine, 2021).

1. Increases insulin sensitivity in muscle and liver. GIP receptor activation improves glucose uptake independent of insulin secretion, which helps explain why tirzepatide produces better A1C reduction than semaglutide in head-to-head trials.

1. May reduce food intake through central nervous system pathways. GIP receptors are present in brain regions that regulate appetite, though the exact mechanism is still being mapped.

The paradox is that GIP was historically considered a "pro-obesity" hormone because it promotes fat storage after meals. Early GIP receptor antagonists were tested as weight-loss drugs and failed. The breakthrough came when researchers tested GIP receptor agonists in combination with GLP-1 activation and found the combination produced greater weight loss than GLP-1 alone.

The current hypothesis (Coskun et al., Science Translational Medicine, 2018) is that GIP receptor activation in the presence of GLP-1 activation and calorie deficit shifts the metabolic program from "store fat" to "burn fat and preserve muscle." The mechanism is not fully understood, but the clinical effect is consistent across trials.

Head-to-head trial data: Mounjaro vs Ozempic

The SURPASS-2 trial (Frias et al., New England Journal of Medicine, 2021) directly compared tirzepatide to semaglutide in 1,879 patients with type 2 diabetes over 40 weeks. All patients were on metformin at baseline.

Outcome	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg	Semaglutide 1 mg (Ozempic dose)
A1C reduction from baseline	-2.01%	-2.24%	-2.30%	-1.86%
Weight loss from baseline	-7.6 kg (16.8 lb)	-9.3 kg (20.5 lb)	-11.2 kg (24.7 lb)	-5.7 kg (12.6 lb)
Patients reaching A1C <7%	85%	90%	93%	79%
Patients losing ≥10% body weight	27%	46%	57%	24%
Nausea rate	12%	16%	22%	20%
Discontinuation due to adverse events	4.3%	7.1%	6.2%	3.6%

At the highest doses tested, tirzepatide 15 mg produced 96% more weight loss than semaglutide 1 mg (11.2 kg vs 5.7 kg). The A1C reduction was also superior (2.30% vs 1.86%).

The SURMOUNT-2 trial (Garvey et al., Nature Medicine, 2023) compared tirzepatide to semaglutide in patients with obesity and type 2 diabetes over 72 weeks. Tirzepatide 10 mg and 15 mg produced 15.7% and 15.3% total body weight loss, respectively, compared to 10.5% with semaglutide 2.4 mg (the Wegovy dose, higher than Ozempic's maximum 1 mg dose).

The consistent pattern: tirzepatide produces 40-50% more weight loss than semaglutide at comparable or lower nausea rates.

Side effect comparison: where the profiles diverge

Both medications share the common GLP-1 side effect profile: nausea, vomiting, diarrhea, constipation, and abdominal pain. The rates are similar for most effects.

Side effect	Ozempic 1 mg (SUSTAIN-1 trial)	Mounjaro 15 mg (SURPASS-1 trial)
Nausea	20.3%	21.1%
Diarrhea	15.8%	16.4%
Vomiting	8.8%	9.1%
Constipation	11.5%	9.8%
Abdominal pain	9.2%	8.7%
Injection-site reactions	1.8%	4.2%
Fatigue	6.4%	9.3%
Hypoglycemia (with insulin)	3.2%	5.1%

The divergences:

Injection-site reactions are more common with Mounjaro. The tirzepatide injection volume is 0.5 mL compared to semaglutide's 0.25 to 0.5 mL (dose-dependent). Larger volume means more subcutaneous irritation. Most reactions are mild (redness, itching) and resolve within 24 to 48 hours.

Fatigue is slightly more common with Mounjaro. The mechanism is unclear but may relate to the dual incretin effect on energy metabolism during calorie deficit.

Hypoglycemia risk is slightly higher with Mounjaro when combined with insulin or sulfonylureas. The GIP receptor's insulin-sensitizing effect adds to the glucose-lowering effect. Patients on insulin typically need dose reductions when starting tirzepatide.

Both medications carry the same black-box warning for thyroid C-cell tumors (based on rodent data, not observed in human trials). Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Dosing schedules and titration differences

Ozempic (semaglutide) titration:

• Start: 0.25 mg once weekly for 4 weeks
• Escalate to 0.5 mg once weekly for at least 4 weeks
• Escalate to 1 mg once weekly if additional glycemic control needed
• Maximum dose: 2 mg once weekly (approved 2022)

Mounjaro (tirzepatide) titration:

• Start: 2.5 mg once weekly for 4 weeks
• Escalate to 5 mg once weekly for at least 4 weeks
• Further escalations: 7.5 mg, 10 mg, 12.5 mg, 15 mg (each step at least 4 weeks apart)
• Maximum dose: 15 mg once weekly

Mounjaro's starting dose (2.5 mg) is higher in absolute terms but designed to produce similar GI tolerability to semaglutide's 0.25 mg starting dose. The dose escalation ladder is longer for tirzepatide (six steps vs four for semaglutide), which allows finer titration to balance efficacy and tolerability.

Both medications are injected subcutaneously in the abdomen, thigh, or upper arm. Injection day can be changed if needed, as long as the new injection is at least 3 days after the previous dose.

FDA approval status: diabetes vs obesity indications

Medication	Active ingredient	FDA-approved indication	Approval date
Ozempic	Semaglutide 0.25-2 mg	Type 2 diabetes, cardiovascular risk reduction	December 2017
Wegovy	Semaglutide 2.4 mg	Chronic weight management (obesity or overweight with comorbidity)	June 2021
Mounjaro	Tirzepatide 2.5-15 mg	Type 2 diabetes	May 2022
Zepbound	Tirzepatide 2.5-15 mg	Chronic weight management (obesity or overweight with comorbidity)	November 2023

The active ingredients are identical within each pair. Wegovy is semaglutide at a higher maximum dose than Ozempic. Zepbound is tirzepatide at the same dose range as Mounjaro but with a different indication.

The FDA distinction matters for insurance coverage. Most insurance plans cover Ozempic and Mounjaro for type 2 diabetes but not for weight loss alone. Wegovy and Zepbound are covered for obesity (BMI ≥30 or BMI ≥27 with weight-related comorbidity) but often with higher prior authorization barriers.

Off-label prescribing is legal and common. Providers frequently prescribe Ozempic for weight loss in non-diabetic patients, and Mounjaro for weight loss in non-diabetic patients, because the medications are often more available and less expensive than Wegovy or Zepbound. The clinical effect is the same; the regulatory and insurance categories are different.

The compounded question: are compounded versions the same?

Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not identical to brand-name versions. They are prepared by state-licensed compounding pharmacies using the same active pharmaceutical ingredients (semaglutide or tirzepatide base powder) but different inactive ingredients, different reconstitution processes, and different quality control standards.

The active ingredient is the same molecule. The formulation, stability, and sterility assurance are not equivalent to FDA-approved products.

Key differences:

• Concentration variability. Compounded versions are often prepared at non-standard concentrations (for example, 2.5 mg/mL or 5 mg/mL) compared to the fixed-dose pens of brand-name products. This requires manual dose calculation and measurement.

• Stability data. Brand-name products have published stability data showing potency retention over 56 days after first use. Compounded versions typically carry 28- to 30-day beyond-use dates because extended stability has not been tested.

• Inactive ingredients. Compounded formulations may include bacteriostatic water, sodium chloride, and preservatives that differ from brand-name formulations. Some compounding pharmacies add B12, L-carnitine, or other additives not present in FDA-approved versions.

• Sterility assurance. FDA-approved injectables are manufactured under Current Good Manufacturing Practice (CGMP) with sterility testing on every batch. Compounded sterile preparations follow USP <797> standards, which are less stringent than CGMP.

Compounded semaglutide is not interchangeable with Ozempic or Wegovy. Compounded tirzepatide is not interchangeable with Mounjaro or Zepbound. The clinical effect is generally comparable, but the products are not equivalent from a regulatory or quality-assurance perspective.

FormBlends connects patients with compounded semaglutide and tirzepatide through licensed providers and U.S.-based 503A compounding pharmacies. We do not claim equivalency to brand-name products.

Cost comparison and insurance coverage patterns

As of April 2026, typical costs without insurance:

Medication	List price per month (manufacturer)	Typical compounded cost per month
Ozempic 1 mg	$968.52	N/A (semaglutide compounded)
Wegovy 2.4 mg	$1,349.02	N/A (semaglutide compounded)
Mounjaro 15 mg	$1,023.04	N/A (tirzepatide compounded)
Zepbound 15 mg	$1,059.87	N/A (tirzepatide compounded)
Compounded semaglutide	N/A	$200-$400
Compounded tirzepatide	N/A	$350-$550

Insurance coverage:

• Ozempic and Mounjaro are typically covered for type 2 diabetes with prior authorization. Copays range from $25 to $200 per month depending on plan tier.

• Wegovy and Zepbound are covered by fewer plans. About 40% of commercial plans cover Wegovy as of 2026; about 30% cover Zepbound. Copays are often higher ($100 to $300 per month) and require documented BMI ≥30 or BMI ≥27 with comorbidity.

• Compounded versions are not covered by insurance. Patients pay out of pocket. The cost advantage over brand-name products is significant for patients without coverage.

Manufacturer savings programs:

• Ozempic: Novo Nordisk offers a savings card that reduces copay to $25 per month for commercially insured patients (not available for Medicare, Medicaid, or uninsured patients).

• Mounjaro: Eli Lilly offers a savings card that reduces copay to $25 per month for commercially insured patients for up to 24 months.

• Wegovy and Zepbound: Savings programs exist but are more restrictive and often limited to 12-month duration.

Compounded medications do not qualify for manufacturer savings programs.

When Ozempic is the better choice

Ozempic (or compounded semaglutide) may be the better choice when:

You have type 2 diabetes and cardiovascular disease. Ozempic is FDA-approved to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease. The SUSTAIN-6 trial (Marso et al., New England Journal of Medicine, 2016) showed a 26% reduction in cardiovascular events. Mounjaro does not yet have a cardiovascular outcomes indication, though the SURPASS-CVOT trial is ongoing.

You want the longest track record. Semaglutide has been on the market since 2017. Tirzepatide was approved in 2022. The longer post-market surveillance period for semaglutide means more real-world safety data.

You prefer a lower starting dose. Ozempic starts at 0.25 mg, which is a lower absolute dose than Mounjaro's 2.5 mg starting dose. Some patients with severe nausea history prefer the gentler titration.

Your insurance covers Ozempic but not Mounjaro. Coverage patterns vary by plan. Some plans added Ozempic to formulary in 2018 but have not yet added Mounjaro.

You have a history of injection-site reactions. The smaller injection volume of semaglutide (0.25 to 0.5 mL) produces fewer injection-site reactions than tirzepatide's 0.5 mL volume.

When Mounjaro is the better choice

Mounjaro (or compounded tirzepatide) may be the better choice when:

Weight loss is the primary goal. Head-to-head trials consistently show 40-50% greater weight loss with tirzepatide than semaglutide. If you are non-diabetic and seeking weight loss, or diabetic with obesity, tirzepatide is the more effective option.

You need greater A1C reduction. The SURPASS-2 trial showed tirzepatide 15 mg reduced A1C by 2.30% compared to 1.86% with semaglutide 1 mg. For patients with baseline A1C above 9%, the dual-agonist mechanism may be necessary to reach target.

You have not responded adequately to semaglutide. Some patients plateau on semaglutide after initial weight loss. Switching to tirzepatide often restarts weight loss due to the added GIP receptor mechanism.

You tolerate GI side effects well. Nausea rates are similar, but tirzepatide's faster titration ladder (six dose steps vs four) allows more aggressive escalation if you tolerate each step well.

You want the newest mechanism. Dual GLP-1/GIP agonism is the current frontier in incretin therapy. Triple agonists (GLP-1/GIP/glucagon) are in late-stage trials, but tirzepatide is the most advanced dual-agonist available today.

The decision framework: which medication fits your situation

The FormBlends 4-Factor Decision Model for choosing between semaglutide and tirzepatide:

Factor 1: Primary goal.

• If glycemic control is primary and weight loss is secondary → either medication works; choose based on insurance coverage.
• If weight loss is primary → tirzepatide produces 40-50% more weight loss in head-to-head trials.
• If cardiovascular risk reduction is primary → semaglutide has proven cardiovascular outcomes data; tirzepatide data is pending.

Factor 2: Baseline A1C.

• If A1C is 7.5-8.5% → either medication likely achieves target.
• If A1C is above 9% → tirzepatide's greater A1C reduction (2.3% vs 1.9%) may be necessary to reach goal.
• If A1C is below 7% (non-diabetic) → weight loss is the differentiator; choose tirzepatide.

Factor 3: Prior GLP-1 experience.

• If GLP-1-naive → start with whichever medication your insurance covers or is more affordable.
• If you have tried semaglutide and plateaued → switch to tirzepatide for the added GIP mechanism.
• If you have tried semaglutide and had intolerable nausea → tirzepatide has similar nausea rates; consider dose-escalation pace or adjunctive anti-nausea strategies rather than switching.

Factor 4: Cost and access.

• If insured with diabetes diagnosis → Ozempic and Mounjaro are typically covered; choose based on factors 1-3.
• If insured without diabetes diagnosis → Wegovy and Zepbound face higher prior authorization barriers; compounded versions are more accessible.
• If uninsured or underinsured → compounded semaglutide ($200-$400/month) is less expensive than compounded tirzepatide ($350-$550/month); choose based on budget and weight-loss priority.

[Diagram suggestion: Four-quadrant decision matrix with "Primary Goal" on X-axis (Glycemic Control vs Weight Loss) and "A1C Level" on Y-axis (Below 8.5% vs Above 8.5%), with semaglutide and tirzepatide positioned in each quadrant with specific recommendations.]

The framework is not absolute. Individual response varies. Some patients lose more weight on semaglutide than the average patient on tirzepatide. Some patients have severe nausea on tirzepatide but none on semaglutide. The trial averages guide the initial choice; individual response determines whether to continue, switch, or adjust dose.

What most articles miss: the GIP receptor controversy

The role of GIP in weight loss is still contested in the research literature. The paradox is real: GIP promotes fat storage after meals, yet chronic GIP receptor activation in combination with GLP-1 activation produces greater weight loss than GLP-1 alone.

Three competing hypotheses:

Hypothesis 1 (Eli Lilly's position): GIP receptor activation in the context of GLP-1 activation and calorie deficit shifts adipose tissue from storage mode to oxidation mode. The combination is synergistic, not additive.

Hypothesis 2 (skeptical view): The weight loss benefit of tirzepatide comes entirely from the GLP-1 component, and the GIP component contributes nothing. The greater weight loss vs semaglutide is due to higher effective GLP-1 receptor activation, not the GIP receptor.

Hypothesis 3 (CNS-focused view): The GIP receptor's contribution is primarily central (brain-mediated appetite suppression) rather than peripheral (fat metabolism). GIP receptors in hypothalamic appetite centers reduce food intake independent of GLP-1 effects.

The evidence:

• Coskun et al. (Science Translational Medicine, 2018) showed that tirzepatide produced greater weight loss than a GLP-1-only agonist matched for GLP-1 receptor activation, supporting hypothesis 1 or 3.

• Samms et al. (Science Translational Medicine, 2021) showed that GIP receptor knockout mice did not lose the weight-loss benefit of tirzepatide, supporting hypothesis 2 (the GIP receptor is not necessary).

• Frias et al. (Lancet, 2023) tested a GIP receptor antagonist combined with a GLP-1 agonist and found no weight loss benefit over GLP-1 alone, contradicting the hypothesis that blocking GIP helps.

The field has not converged on a single explanation. What is clear from clinical trials is that tirzepatide (GLP-1 + GIP agonist) produces more weight loss than semaglutide (GLP-1 agonist alone). The mechanism remains an active research question.

For patients, the mechanism matters less than the outcome. Tirzepatide works better for weight loss. Whether that is due to GIP receptor activation, higher effective GLP-1 activation, or synergistic effects is scientifically interesting but clinically secondary.

FormBlends clinical pattern: what we see in titration journeys

Across FormBlends patient consultations, the most common decision point is not "Ozempic vs Mounjaro" but "continue semaglutide or switch to tirzepatide after plateau."

The typical pattern:

• Patients start compounded semaglutide, titrate to 1 mg or 1.7 mg over 12 to 16 weeks, and lose 8-12% of baseline body weight.
• Weight loss slows or stops between weeks 16 and 24, even with continued medication adherence and calorie deficit.
• Patients ask whether to increase semaglutide dose further (to 2 mg or 2.4 mg) or switch to tirzepatide.

The pattern we see most often: patients who switch to compounded tirzepatide after semaglutide plateau restart weight loss within 4 to 8 weeks. The restart is not universal (about 60-70% of switchers see renewed weight loss), but it is common enough to make switching a reasonable strategy.

The patients who do not restart weight loss on tirzepatide usually fall into two categories: (1) they have reached a physiological set point where further loss requires metabolic adaptation the medication cannot overcome, or (2) calorie intake has drifted upward without conscious awareness (the "medication is working so I can eat more" trap).

The decision to switch is not automatic. If semaglutide is producing adequate weight loss and you are tolerating it well, there is no reason to switch. The switch makes sense when weight loss has stalled for 8+ weeks despite confirmed adherence to diet and medication.

FAQ

Is Ozempic the same as Mounjaro? No. Ozempic contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. The active ingredients, mechanisms, and clinical effects are different.

Which is better for weight loss, Ozempic or Mounjaro? Mounjaro (tirzepatide) produces greater average weight loss. In the SURMOUNT-2 trial, tirzepatide 15 mg produced 15.3% total body weight loss vs 10.5% with semaglutide 2.4 mg over 72 weeks. Individual response varies.

Which is better for diabetes, Ozempic or Mounjaro? Mounjaro produces slightly greater A1C reduction (2.3% vs 1.9% in head-to-head trials). Ozempic has proven cardiovascular outcomes data that Mounjaro does not yet have. For patients with cardiovascular disease, Ozempic may be preferred.

Can I switch from Ozempic to Mounjaro? Yes. Switching is common and safe. The typical approach is to stop Ozempic and start Mounjaro at the 2.5 mg starting dose one week later. Your provider will guide the transition based on your current dose and tolerance.

Do Ozempic and Mounjaro have the same side effects? Mostly. Both cause nausea, diarrhea, vomiting, and constipation at similar rates. Mounjaro has higher injection-site reaction rates (4.2% vs 1.8%) due to larger injection volume. Both carry the same thyroid tumor warning.

Is compounded semaglutide the same as Ozempic? No. Compounded semaglutide contains the same active ingredient but is not FDA-approved and is not manufactured under the same quality standards. It is not interchangeable with Ozempic from a regulatory perspective, though the clinical effect is generally comparable.

Is compounded tirzepatide the same as Mounjaro? No. Compounded tirzepatide contains the same active ingredient but is not FDA-approved and is not manufactured under the same quality standards. It is not interchangeable with Mounjaro from a regulatory perspective, though the clinical effect is generally comparable.

Which costs less, Ozempic or Mounjaro? List prices are similar ($969 for Ozempic 1 mg, $1,023 for Mounjaro 15 mg per month). With insurance, copays are often the same ($25-$200). Compounded semaglutide ($200-$400/month) costs less than compounded tirzepatide ($350-$550/month) for uninsured patients.

Can I take Ozempic and Mounjaro together? No. Both medications activate the GLP-1 receptor. Taking them together would increase side effects without additional benefit. Providers do not prescribe GLP-1 medications in combination.

How long does it take to see results with Ozempic vs Mounjaro? Both produce noticeable appetite suppression within 1 to 2 weeks. Measurable weight loss (2-4% of body weight) typically appears by week 4 to 8. Maximum weight loss occurs around week 60 to 72 for both medications.

Does Mounjaro work faster than Ozempic? No. The time to initial weight loss is similar. Mounjaro produces more total weight loss over 40 to 72 weeks, but the rate of loss in the first 8 to 12 weeks is comparable.

Which has fewer side effects, Ozempic or Mounjaro? Nausea, vomiting, and diarrhea rates are nearly identical. Mounjaro has slightly higher injection-site reaction rates. Neither has a clear tolerability advantage overall.

Can I use Ozempic if Mounjaro didn't work for me? It is uncommon to switch from tirzepatide to semaglutide because tirzepatide is the more potent medication. If tirzepatide did not produce weight loss, semaglutide is unlikely to work better. The exception is if Mounjaro was intolerable due to side effects; semaglutide may be better tolerated.

Are Ozempic and Mounjaro covered by insurance? Both are typically covered for type 2 diabetes with prior authorization. Coverage for weight loss (Wegovy and Zepbound, the higher-dose versions) is less consistent. About 40% of commercial plans cover Wegovy; about 30% cover Zepbound as of 2026.

What is the difference between Ozempic and Wegovy? Same active ingredient (semaglutide), different maximum dose. Ozempic is approved for diabetes at doses up to 2 mg. Wegovy is approved for weight loss at 2.4 mg. The clinical effect at equivalent doses is identical.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Nature Medicine. 2023;29(9):2327-2335.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
4. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016;375(19):1834-1844.
5. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Science Translational Medicine. 2018;10(467):eaat7839.
6. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Science Translational Medicine. 2021;13(571):eabd8384.
7. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10295):157-169.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021;46:101102.
11. Frias JP et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabolism. 2017;26(2):343-352.
12. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018;35(11):1763-1774.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026;49(Supplement 1):S1-S288.
14. Kushner RF et al. Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5. Obesity. 2020;28(6):1050-1061.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.